Acquisitions:
1. Zydus Wellness acquires U.K. based Comfort Click for $335 Million (INR 2,846 Cr).
2. Intas & Accord signs Agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium.
3. AbbVie to acquire Gilgamesh Pharmaceuticals’ bretisilocin for US$1.2 Billion.
4. Sandoz to acquire Just–Evotec Biologics facility for US$300 Million.
5. Doximity acquires Pathway Medical for $63 Million to bolster AI tools for doctors.
6. Senores Pharma to Acquire Two Products of USFDA Approved ANDAs from Teva Pharma USA.
Licensing:
1. Lupin partners with Sandoz to commercialise Ranibizumab biosimilar.
2. Santhera Pharma inks agreement with Ikris Pharma Network for distribution of Agamree in India.
3. Bayer licenses early-stage cancer drug from KRAS biotech for up to US$1.3 Billion.
4. Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers.
Investments:
1. Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline.
2. Wugen raises $115m for trial of T-cell cancer therapy.
3. ProVerum raises US$80 Million for stent aimed at enlarged prostates.
4. Arnatar Therapeutics secured US $52M Series A to develop RNA therapies for Alagille syndrome.
5. 3D-printed orthopedic implant maker restor3d raises US$104 Million.
Co-development:
1. Akums Drugs inks USD50 Million Medicine Supply Deal to set up manufacturing facility in Zambia.
2. Shilpa Medicare inks pact for building new pharma manufacturing facility in Saudi Arabia.
3. Sartorius Stedim Biotech and Nanotein partner to advance cell therapy manufacturing.
4. Veeva Systems collaborates with Amgen to further accelerate clinical trial innovation. 550M Replicate research deal
5. Novo Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal
Aagami Updates:
1. New Out-Licensing Assignment from Belgian client: with antibiotic-free selection technology in E. coli. Increased Yield, genetic stablity and easy to use.
2. Success for US besed client with Novel and portable MRI system: In the June to August 2025 timeframe, Aagami secured 12 Investments for the client. More in advanced discussions, including a $25 Million term sheet.
3. Akshay Bavaria from Aagami is attending Asia Bio Partnering Forum 2025 (Sept 9–10, Singapore) and Digital Partnering Days (Sept 16–17) —Only 4 time options remain open in our calendar. Please send your meeting request at the earliest.
4. Aagami Research Team (ART) has prepared a Business Research report , highlighting select cross border deals of Indian companies covering Jan 2023 – Mar 2025.
a. The deals reveal robust activity across acquisitions, investments, licensing, and strategic collaborations, highlighting India’s expanding global footprint.
b. If you would like to receive a complimentary copy of the report, please contact us.
5. Aagami to participate in the following partnering conferences (2025):
a. ASIA BIO Partnering Forum | SEP 09-10, 2025 | Singapore
b. Bio Japan | OCT 08-10, 2025 | PACIFICO Yokohama
c. BIOPLUS-INTERPHEX KOREA| OCT 15-17, 2025 | COEX Seoul
d. BIO-EUROPE | NOV 03-05, 2025 | Vienna, Austria
Select opportunities available with us:
For Partnering/Licensing/ Co-development:
1. Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.
2. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients under 72 years of age).
4. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.
For Acquisition:
1. A High Multiple ROI by acquiring clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready).
2. Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic.
3. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics.
4. Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU, results expected by Dec 2025).
For Investment:
1. High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market). With over US $70 Million raised in current round, our client is offering special terms to invest in current B-4/B-5 round. Expected ROI is 2-4x in 12-18 months via an IPO, strategic M&A, or private equity buyout.
Hope you found the content useful. We welcome your feedback and queries.